1 SECONDARY SAFETY ENDPOINTS – UP TO MONTH 6

1.1 TREATMENT-ADVERSE EVENTS UP TO MONTH 6

A total of 48 TEAEs were reported for 18 patients (78.3%) from Day 1 (post infusion) up to Month 6.

Severity

The majority of the reported TEAEs were of Grade 1 (mild) or Grade 2 (moderate) intensity (34 and 12 events; respectively). These TEAEs were mostly gastrointestinal disorders (12 events) followed by general disorders and administration site conditions (10 events) and by nervous system disorders (7 events). Two TEAEs, both of mild severity, reported for 2 patients (8.7%), were considered as serious.

Two TEAEs, reported for 2 patients (8.7%), were considered as severe (Grade 3 intensity): an event of dysplastic hepatic nodule (MedDRA preferred term: Hepatic Mass) and an event of prostatic adenocarcinoma (MedDRA preferred term: Prostate Cancer).

None of the reported TEAEs were of Grade 4 or Grade 5 intensity.

Relationship to the study drug

Most of the TEAEs (30 events) were not related to the study drug but to the patients' condition and expected in the context of the study pathology. The remaining 18 events, reported for 10 patients, were considered as related to the study drug in the clinical database. These TEAEs were mostly in the SOC of Gastrointestinal disorders (5 events), General disorders and administration site conditions (5 events), and Investigations (4 events):

1.2 VITAL SIGNS, PHYSICAL FINDINGS AND OTHER OBSERVATIONS RELATED TO SAFETY

1.2.1 Vital signs

Overall, no significant changes were observed in vital signs during the study period.

1.2.2 Physical examination

Overall, no significant changes were observed in physical examinations during the study period.

1.2.3 ECG

No clinically significant abnormalities were reported up to Month 6.

1.2.4 Imagery

No signs of portal vein thrombosis or thrombosis of other hepatic vein branches were detected at any time point for all participants.

No clinically significant signs of heart failure or other pathology were reported.

1.3 LABORATORY PARAMETERS

1.3.1 Hematology

From baseline up to Month 6, no significant change was observed in mean hemoglobin levels, and in mean leukocyte and neutrophil counts by dose cohort, by fibrosis stage, by number of cells administered, and by number of injections.

1.3.2 Biochemistry

From baseline up to Month 6, no significant change was observed in mean levels of creatinine, urea, sodium, and α-fetoprotein by dose cohort, by fibrosis stage, by number of cells administered and by number of injections.

The levels of most of the tested liver enzymes (ALT, AST, GGT) tended to normalize by Month 6, especially in F3 patients.

Total bilirubin levels gradually decreased throughout the study, particularly in patients with higher values at baseline.

Albumin levels did not significantly change throughout the study.

Fasting glucose and insulin levels tended to decrease over time, particularly in F3 patients.

Triglyceride levels tended to decrease and HDL levels tended to increase throughout the study.

Overall, no significant changes were observed in uric acid levels from baseline up to Month 6.

1.3.3 Coagulation

No significant changes in coagulation parameters were observed on Month 6 compared to baseline values.

1.3.4 Urine analysis

The data on urine analysis are in line with the study pathology with non-clinically significant positive albumin, protein, and glucose concentrations in some patients.